Table 4 Prognostic performance with the addition of Reti-CVD to the QRISK3 in the UK biobank dataset
|  | Non-statin cohort (n = 42,473) |  | Stage 1 hypertension cohort (n = 11,966) |  | Middle-aged Cohort (n = 38,941) |  |
|---|---|---|---|---|---|---|
Models | C statistic (95% CI) | p value | C statistic (95% CI) | p value | C statistic (95% CI) | p value |
Reti-CVD | 0.624 (0.615–0.633) | NA | 0.591 (0.575–0.608) | NA | 0.611 (0.600 -0.622 ) | NA |
Reti-CVD plus age, gender | 0.699 (0.690–0.709) | NA | 0.663 (0.644–0.681) | NA | 0.681 (0.669–0.692) | NA |
QRISK3 | 0.682 (0.672–0.692) | NA | 0.639 (0.620–0.658) | NA | 0.650 (0.638–0.662) | NA |
Reti-CVD plus QRISK3 | 0.696 (0.686–0.706) | NA | 0.652 (0.633–0.671) | NA | 0.674 (0.661–0.686) | NA |
 Δ Reti-CVD plus QRISK3 versus QRISK3 | 0.014 (0.010–0.017) | < 0.001 | 0.013 (0.007–0.019) | < 0.001 | 0.023 (0.018–0.029) | < 0.001 |
NRI | ||||||
 Continuous NRI (95% CI) | 0.133 (0.088–0.173) | < 0.001 | 0.094 (0.008–0.174) | 0.033 | 0.248 (0.190–0.301) | < 0.001 |